Atogepant (2) – Aquipta®
Acute treatment of migraine
Characteristics
| Start date | 01.07.2026 |
|---|---|
| Resolution | 17.12.2026 – active procedure |
| INN | Atogepant |
| Brand name | Aquipta® |
| Pharm. company | AbbVie Deutschland GmbH & Co. KG |
| G-BA Procedure ID | D-1339 |
| Therapeutic area | Nervous system diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Atogepant (2) | Aquipta® | AbbVie Deutschland GmbH & Co. KG | Acute treatment of migraine | n.d. | active procedure | |
| Atogepant (1) | Aquipta® | AbbVie Deutschland GmbH & Co. KG | Migraine prophylaxis | 1,386,900–1,726,200 | 100% additional benefit not proven |
<< List of all resolutions